Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous isatuximab in adults with warm autoimmune hemolytic anemia
NL-OMON51964Phase 2Active, not recruiting
- Sponsor
- Sanofi
- Start
- Oct 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of isatuximab in warm autoimmune hemolytic anemia (wAIHA) (6 arms), sponsored by Sanofi. Primary endpoints: Safety and tolerability and Overall response rate or complete response at Day 85. Started Oct 2022; status: active, not recruiting.
02
Drugs
isatuximab
03
Conditions
warm autoimmune hemolytic anemia (wAIHA)
Beyond the preview
Go deeper on NL-OMON51964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51964.